Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Daiichi Sankyo
Federal Trade Commission

Generated: December 11, 2017

DrugPatentWatch Database Preview

Details for Patent: 4,920,143

« Back to Dashboard

Summary for Patent: 4,920,143

Title: Hydro-monobenzoporphyrin wavelength-specific cytotoxic agents
Abstract:A group of hydro-monobenzoporphyrins "green porphyrins" (Gp) having absorption maxima in the range of 670-780 nanometers is useful in treating disorders or conditions which are subject to hematoporphyrin derivative (HPD) treatment in the presence of light, or in treating virus, cells and tissues generally to destroy unwanted targets. The use of the Gp of the invention permits the irradiation to use wavelengths other than those absorbed by blood. The Gp of the invention may also be conjugated to ligands specific for receptor or to specific immunoglobulins or fragments thereof to target specific tissues or cells for the radiation treatment. Use of these materials permits lower levels of drug to be used, thus preventing side reactions which might destroy normal tissues.
Inventor(s): Levy; Julia G. (Vancouver, CA), Dolphin; David (Vancouver, CA), Chow; Jack K. (Burnaby, CA), Sternberg; Ethan (Vancouver, CA)
Assignee: University of British Columbia (Vancouver, CA)
Application Number:07/221,161
Patent Claim Types:
see list of patent claims
Compound; Composition;

No matches for this query

International Patent Family for Patent: 4,920,143

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria104859► Subscribe
Austria127696► Subscribe
Austria209650► Subscribe
Australia1038888► Subscribe
Australia3825889► Subscribe
Australia618725► Subscribe
Australia638675► Subscribe
Canada1333442► Subscribe
Canada1339927► Subscribe
Germany10199008► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Farmers Insurance
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: